Literature DB >> 23143677

Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.

Karim Salazar-Salinas1, Carlos Kubli-Garfias, Jorge M Seminario.   

Abstract

This is a preliminary cross multidisciplinary theoretical-computational approach for the design of a drug delivery system based on immunoconjugated carbon nanotube against HER2- overexpressing cancer cells. This drug delivery system allows the release of an encapsulated cytotoxic cocktail in a controlled manner under pulsed radio frequency (RF) irradiation. Our effort is focused on the computational aided design of a high affinity bispecific anti-HER2 antibody and an opening mechanism of the carbon nanotube (CNT) based cytotoxic carrier for controlling multiple drug release. We study the main interactions between the antibody and the antigen by a computational scanning mutagenesis approach of trastuzumab and pertuzumab fragment antigen binding (Fab) structures in order to enhance their binding affinity. Then, each Fab fragments is joined by a polypeptide linker which should be stable enough to avoid the "open form" of antibody. On the other hand, we also conjugate the engineered antibody to functionalized CNTs (f-CNTs), which encapsulate the inhibitors of the HER2/PI3K/Akt/mTOR signaling pathway. We take advantage of the fact that f-CNT converts the RF radiation absorption into heat release. A pulsed laser at 13.45 MHz increments the temperature around 40 °C for triggering the nano-caps destabilization, which allows the switching of the opening mechanism of the drug carrier. Nano-caps will be a dual pH/temperature responsive in order to take advantage of lysosome characteristic (acidic pH) and heat release from the carrier. Nano-caps are functionalized with organic amide moieties, which hydrolyze quickly at an acidic pH into primary amines, and protonated amines generate repulsion interactions with other charged species, which trigger the cytotoxics release.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143677     DOI: 10.1007/s00894-012-1638-2

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  100 in total

1.  Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

Authors:  Brian R Miller; Stephen J Demarest; Alexey Lugovskoy; Flora Huang; Xiufeng Wu; William B Snyder; Lisa J Croner; Norman Wang; Aldo Amatucci; Jennifer S Michaelson; Scott M Glaser
Journal:  Protein Eng Des Sel       Date:  2010-05-10       Impact factor: 1.650

2.  Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type.

Authors:  Kostas Kostarelos; Lara Lacerda; Giorgia Pastorin; Wei Wu; Sébastien Wieckowski; Jacqueline Luangsivilay; Sylvie Godefroy; Davide Pantarotto; Jean-Paul Briand; Sylviane Muller; Maurizio Prato; Alberto Bianco
Journal:  Nat Nanotechnol       Date:  2007-01-28       Impact factor: 39.213

Review 3.  Integrins in breast cancer dormancy.

Authors:  Stephanie M Pontier; William J Muller
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

Review 4.  Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Authors:  Jared A Gollob; Scott Wilhelm; Chris Carter; Susan L Kelley
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

Review 5.  HER2 fragmentation and breast cancer stratification.

Authors:  Joaquín Arribas; Josep Lluís Parra-Palau; Kim Pedersen
Journal:  Clin Cancer Res       Date:  2010-08-03       Impact factor: 12.531

6.  Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells.

Authors:  Hélène Dumortier; Stéphanie Lacotte; Giorgia Pastorin; Riccardo Marega; Wei Wu; Davide Bonifazi; Jean-Paul Briand; Maurizio Prato; Sylviane Muller; Alberto Bianco
Journal:  Nano Lett       Date:  2006-07       Impact factor: 11.189

7.  Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes and nano-onions on human skin fibroblast.

Authors:  Lianghao Ding; Jackie Stilwell; Tingting Zhang; Omeed Elboudwarej; Huijian Jiang; John P Selegue; Patrick A Cooke; Joe W Gray; Fanqing Frank Chen
Journal:  Nano Lett       Date:  2005-12       Impact factor: 11.189

8.  Production of large amounts of hydrogen peroxide by human tumor cells.

Authors:  T P Szatrowski; C F Nathan
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

9.  The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.

Authors:  Jonathan Zalevsky; Irene W L Leung; Sher Karki; Seung Y Chu; Eugene A Zhukovsky; John R Desjarlais; David F Carmichael; Chris E Lawrence
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

10.  Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth.

Authors:  Silke Hampel; Doreen Kunze; Diana Haase; Kai Krämer; Mandy Rauschenbach; Manfred Ritschel; Albrecht Leonhardt; Jürgen Thomas; Steffen Oswald; Volker Hoffmann; Bernd Büchner
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

View more
  3 in total

1.  From GROMACS to LAMMPS: GRO2LAM : A converter for molecular dynamics software.

Authors:  Hernán Chávez Thielemann; Annalisa Cardellini; Matteo Fasano; Luca Bergamasco; Matteo Alberghini; Gianmarco Ciorra; Eliodoro Chiavazzo; Pietro Asinari
Journal:  J Mol Model       Date:  2019-05-07       Impact factor: 1.810

2.  Molecular dynamics simulations of the orientation properties of cytochrome c on the surface of single-walled carbon nanotubes.

Authors:  Bing Zhang; Jia Xu; Shu-Fan Mo; Jian-Xi Yao; Song-Yuan Dai
Journal:  J Mol Model       Date:  2016-11-30       Impact factor: 1.810

3.  On the vibrational behavior of single- and double-walled carbon nanotubes under the physical adsorption of biomolecules in the aqueous environment: a molecular dynamics study.

Authors:  S Ajori; R Ansari; M Darvizeh
Journal:  J Mol Model       Date:  2016-02-22       Impact factor: 1.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.